Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Phase 3 trial of CagriSema in obesity without T2DM
503A compounding pharmacies may work with materials which, in addition to being accompanied by a valid certificate of analysis (CoA) and manufactured in an FDA registered facility, must meet one of the below three requirements: Complies with an applicable USP or NF monograph if one exists* Is a component of an FDA-approved drug product if an applicable USP or NF monograph does not exist
Product Attributes Customization Available CAS No
Hands, underarms, and feet
Researchers will reveal detailed results for a fixed-dose combination of semaglutide and long-acting amylin analogue cagrilintide in Efficacy and Safety of CagriSema 2.4mg/2.4 mg in Adults with Overweight/Obesitythe REDEFINE 1 and REDEFINE 2 Clinical Trials
US$ 21.60
US$ 26.75
US$ 21.96
US$ 21.16
US$ 26.20
US$ 22.47
US$ 28.84
US$ 26.94
